These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12365652)

  • 1. Use of fractionated doses of iodine-131 for ablation of thyroid remnants.
    Wang SJ; Liu TJ
    Zhonghua Yi Xue Za Zhi (Taipei); 2002 Jul; 65(7):336-40. PubMed ID: 12365652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
    Zaman Mu; Toor R; Kamal S; Maqbool M; Habib S; Niaz K
    J Pak Med Assoc; 2006 Aug; 56(8):353-6. PubMed ID: 16967785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.
    Muratet JP; Giraud P; Daver A; Minier JF; Gamelin E; Larra F
    J Nucl Med; 1997 Sep; 38(9):1362-8. PubMed ID: 9293788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
    Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
    Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.
    Pacini F; Capezzone M; Elisei R; Ceccarelli C; Taddei D; Pinchera A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1499-501. PubMed ID: 11932271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.
    David A; Blotta A; Bondanelli M; Rossi R; Roti E; Braverman LE; Busutti L; degli Uberti EC
    J Nucl Med; 2001 Oct; 42(10):1470-5. PubMed ID: 11585859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma.
    Lee HJ; Rha SY; Jo YS; Kim SM; Ku BJ; Shong M; Kim YK; Ro HK
    Am J Clin Oncol; 2007 Feb; 30(1):63-8. PubMed ID: 17278897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
    Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan.
    Pineda JD; Lee T; Ain K; Reynolds JC; Robbins J
    J Clin Endocrinol Metab; 1995 May; 80(5):1488-92. PubMed ID: 7744991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
    Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
    J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.
    Lee JI; Chung YJ; Cho BY; Chong S; Seok JW; Park SJ
    Surgery; 2013 Jun; 153(6):828-35. PubMed ID: 23489940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer.
    Ha S; Oh SW; Kim YK; Koo do H; Jung YH; Yi KH; Chung JK
    J Korean Med Sci; 2015 Jul; 30(7):876-81. PubMed ID: 26130949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer.
    Vermiglio F; Violi MA; Finocchiaro MD; Baldari S; Castagna MG; Moleti M; Mattina F; Pio Lo Presti V; Bonanno N; Trimarchi F
    Thyroid; 1999 Apr; 9(4):387-91. PubMed ID: 10319946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases.
    Filesi M; Signore A; Ventroni G; Melacrinis FF; Ronga G
    J Nucl Med; 1998 Sep; 39(9):1542-6. PubMed ID: 9744339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.